



LASA SUPERGENERICS LIMITED

Corporate Office : Office No . 705, Minerva Estate, Asha Nagar A Wing, O2 Commercial Tower,
Mulund (West) , Mumbai- 400 080
Email : info@lasalabs.com • Website : www.lasalabs.com

Ref. No.: LASA/SE/20-21/35

Tuesday November 24, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
---	---

Dear Sir/Madam,

Subject: Media Release

Attached is the copy of Press Release titled “**Lasa Receives further Injunction from Hon’ble High Court, Bombay restraining its competitor from Manufacturing albendazole in addition to other reliefs which is subject matter of patent infringement case, until disposal of suit**” issued by the company.

You are requested to take the same on your record.

Yours Sincerely

FOR LASA SUPERGENERICS LIMITED



NIDHI KULSHRESHTHA

COMPANY SECRETARY AND COMPLIANCE OFFICER

CIN : L24233MH2016PLC274202

Lasa Receives further Injunction from Hon'ble High Court, Bombay restraining its competitor from Manufacturing albendazole in addition to other reliefs which is subject matter of patent infringement case, until disposal of suit.

The Hon'ble Bombay High Court by its interim order dated 23rd November 2020 has restrained one of our competitor from infringing Lasa's process patent No. 326628 in respect of invention titled "AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5-(PROPYLTHIO)-1H-BENZO [D] IMIDAZOL-2-YLCARBAMATE". The relief granted by the Hon'ble High Court is in addition to the earlier reliefs by which the competitor is restrained from manufacturing and/or dealing in its product by using the Lasa's proprietary and confidential information.

Mumbai, November 24, 2020: Lasa Supergenerics Limited (Lasa), India's leading API manufacturer, announced that it has been granted *Injunction order against its competitor from Hon'ble High Court, Bombay* vide order dated 23rd November 2020.

Commenting on this development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics said: *It is one of the biggest achievements in the history of Lasa, Our Legal Team and Counsels made it possible to achieve this even in this difficult times.*

The receipt of this relief is the milestones for Lasa, as it will restrain its competitor to manufacture and deal in one of the key product and enables the company to continue its leadership for its key products worldwide. We are keeping a close watch in the market in respect of illegal activities of some traders and we are ready to initiate civil and/or criminal actions to protect our invention and proprietary information.

Reliefs as granted by Hon'ble High Court, Bombay which shall continue till the disposal of the suits are as follows:

"(a) pending the hearing and final disposal of the present suit the respondents by itself or through its directors, group companies, associates, divisions, assigns in business, servants, job workers, proprietors, partners, licensees, franchisees, agents, distributors, dealers, stockists and all persons claiming through the respondents directly or indirectly be restrained by a temporary order and injunction of this Hon'ble Court from adopting/using the applicant's patented process which is the subject matter of Patent No.326628 or from manufacturing Albendazole i.e. Methyl 5-(propylthio)-1h-benzo (d) imidazol-2-ylcarbamate by use of the patented process which is the subject matter of Patent

No.326628 or from adopting, using, selling, offering for sale, importing, exporting or dealing in Albendazole i.e. Methyl 5 -(propylthio)-1h-benzo (d) imidazol-2-ylcarbamate manufactured by use of the patented process which is the subject matter of Patent No.326628 of the applicant or any other process as may be substantially similar thereto amounting to infringement of Indian Patent No.326628 of the applicant.

"(b) Pending the hearing and final disposal of the present suit the Respondent Nos. 1 and 2, by itself or through its directors, group companies, associates, divisions, assigns in business, servants, job workers, proprietors, partners, licensees, franchisees, agents, distributors, dealers, stockists and all

persons claiming through the Respondents, directly or indirectly, be restrained by a temporary order and injunction of this Hon'ble Court from selling, offering for sale, importing, exporting or dealing in Albendazole i.e. Methyl 5-(propylthio)-1h-benzo [d] imidazol-2-ylcarbamate manufactured by use of the Confidential Information, details and particulars of which are given in Paragraph 31 of the plaint;

(c) Pending the hearing and final disposal of the present suit the Respondent Nos. 1 and 2, by itself or through its directors, group companies, associates, divisions, assigns in business, servants, job workers, proprietors, partners, licensees, franchisees, agents, distributors, dealers, stockists and all persons claiming through the Respondents, directly or indirectly, be restrained by a temporary order and injunction of this Hon'ble Court from using, making copies of, disclosing / divulging / parting with possession / distributing / circulating to any third parties by any means, mode or method, directly or indirectly, in any manner, the said Confidential Information, details and particulars of which are given in Paragraph 31 of the plaint;

Lasa has subsisting process patent in its name for the invention titled "AN IMPROVED PROCESS FOR THE PREPARATION OF METHYL 5- (PROPYLTHIO)-1H-BENZO [D] IMIDAZOL-2-YLCARBAMATE" and it's products based on the patented process and by use of its confidential information comprised over 85% of the company's FY2020 revenues.

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa is a globally well-trusted API maker of high-quality products accepted by large pharma majors across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has state-of-the-art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company is steadily diversifying into hormonal APIs for human use. More than 25% of its APIs are exported to countries such as Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, and Pakistan.

DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Hitesh Wadhvani

Vice President - Legal, Lasa Supergenerics Limited

Tel: +91 7798888147

E-Mail: hitesh@lasalabs.com